Literature DB >> 22095693

Rate of change in early Huntington's disease: a clinicometric analysis.

Christina Meyer1, Bernhard Landwehrmeyer, Carsten Schwenke, Adam Doble, Michael Orth, Albert C Ludolph.   

Abstract

Sensitive outcome measures for patients with Huntington's disease (HD) are required for future clinical trials. Longitudinal data were collected from a 3-year study of 379 patients suffering from early HD who were not treated by antipsychotics. Progression of UHDRS item scores was evaluated by linear regression and slope, whereas correlation coefficient, standard error, and P values were estimated on the basis of the data of eight evaluations from screening to study end (36 months). For the functional assessment dimension, the proportion of "no" responses at baseline and at study end was determined. Linear progression was observed for the motor score and for all three functional measures (i.e., functional assessment score, independence assessment score, and total functional capacity score). In contrast, there was little evidence for progression of the behavioral assessment score over the study period, whereas the cognitive assessment score was intermediate. Twenty-two motor-score items showed linear progression, with a slope of >0.003. These included all chorea items, finger tapping and pronation/supination (left and right), gait, tongue protrusion, and tandem walking. Different symptom domains and individual items evolved at different rates in this group of patients suffering from early HD. It may be possible to select sensitive items to create a simplified version of the UHDRS, which would be more efficient and more sensitive for the assessment of disease progression in clinical trials and natural history studies.
Copyright © 2011 Movement Disorder Society.

Entities:  

Mesh:

Year:  2011        PMID: 22095693     DOI: 10.1002/mds.23847

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  7 in total

1.  Tracking motor impairments in the progression of Huntington's disease.

Authors:  Jeffery D Long; Jane S Paulsen; Karen Marder; Ying Zhang; Ji-In Kim; James A Mills
Journal:  Mov Disord       Date:  2013-10-21       Impact factor: 10.338

2.  Increased catabolic state in spinocerebellar ataxia type 1 patients.

Authors:  Anja Mähler; Jochen Steiniger; Matthias Endres; Friedemann Paul; Michael Boschmann; Sarah Doss
Journal:  Cerebellum       Date:  2014-08       Impact factor: 3.847

3.  Monitoring Huntington's disease progression through preclinical and early stages.

Authors:  Chris Tang; Andrew Feigin
Journal:  Neurodegener Dis Manag       Date:  2012-08-01

4.  Assessment Scales for Patients with Advanced Huntington's Disease: Comparison of the UHDRS and UHDRS-FAP.

Authors:  Jessica Y Winder; Wilco P Achterberg; Johan Marinus; Sarah L Gardiner; Raymund A C Roos
Journal:  Mov Disord Clin Pract       Date:  2018-08-24

5.  Reduced motivation in the BACHD rat model of Huntington disease is dependent on the choice of food deprivation strategy.

Authors:  Erik Karl Håkan Jansson; Laura Emily Clemens; Olaf Riess; Huu Phuc Nguyen
Journal:  PLoS One       Date:  2014-08-21       Impact factor: 3.240

Review 6.  Exercise in Huntington's Disease: Current State and Clinical Significance.

Authors:  Sandro Manuel Mueller; Jens A Petersen; Hans H Jung
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2019-02-04

7.  Interrater Reliability of the Unified Huntington's Disease Rating Scale-Total Motor Score Certification.

Authors:  Jessica Y Winder; Raymund A C Roos; Jean-Marc Burgunder; Johan Marinus; Ralf Reilmann
Journal:  Mov Disord Clin Pract       Date:  2018-04-15
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.